ArticleTransplantation and cellular therapy2021
Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study.
Open access · hybridAbstract read
In one paragraph
Article in Transplantation and cellular therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.6field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 29 citations in OpenAlex.
- Optimizing Patient Selection for Reduced Nonrelapse Mortality After Reduced-Intensity Conditioning: A CIBMTR Analysis.Transplantation and cellular therapy · 2026Article
- HLA-AJournal of immunology research · 2026Article
- Conditioning intensity in myelodysplastic patients aged ≥ 50 years undergoing allogeneic hematopoietic cell transplantation (allo-HCT): a study on behalf of the chronic malignancies working party of the EBMT.Bone marrow transplantation · 2025Article
- Impact of Conditioning Intensity on Survival in Adult Patients (< 65 Years) With Acute Myeloid Leukemia Receiving Antithymocyte Globulin and Post-Transplantation Cyclophosphamide Based GVHD Prophylaxis.European journal of haematology · 2025Article
- Maintenance therapy with oral decitabine plus cedazuridine after allogeneic stem cell transplantation for myelodysplastic syndrome.Haematologica · 2025Article
- New perspectives on extracorporeal life support: expert teams and precise selection of candidates are transforming pediatric cancer and hematopoietic cell transplantation care.Frontiers in oncology · 2025Article
- Impact of myelofibrosis on patients with myelodysplastic syndromes following allogeneic hematopoietic stem cell transplantation.Journal of translational medicine · 2024Article
- Novel risk assessment for the intensity of conditioning regimen in older patients.Blood advances · 2023Article
- Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT.Bone marrow transplantation · 2023Article
- Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia.Science translational medicine · 2022Article
- Allogeneic Hematopoietic Cell Transplantation and Cellular Therapy.Blood cell therapy · 2021Article
- Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend "when and for whom" in 2021?Haematologica · 2021Review
- BMT for Myelodysplastic Syndrome: When and Where and How.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
55 authors at 20 institutions in 9 countries.
Nelli BejanyanDepartment of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida. Electronic address: nelli.bejanyan@moffitt.org.
Meijie ZhangDivision of Biostatistics, Medical College of Wisconsin, Milwaukee, Wisconsin.
Khalid Bo-SubaitDivision of Biostatistics, Medical College of Wisconsin, Milwaukee, Wisconsin.
Claudio BrunsteinAdult Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota.
Hailin WangDivision of Biostatistics, Medical College of Wisconsin, Milwaukee, Wisconsin.
Erica D WarlickAdult Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota.
Sergio GiraltMemorial Sloan Kettering Cancer Center, New York, New York.
Taiga NishihoriDepartment of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida.
Rodrigo MartinoDivision of Clinical Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Jakob PasswegDivision of Hematology, Department of Internal Medicine, University Hospital Basel, Basel, Switzerland.
Ajoy DiasBeth Israel Deaconess Medical Center, Boston, Massachusetts.
Edward CopelanDepartment of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina.
Gregory HaleDepartment of Hematology/Oncology, Johns Hopkins All Children's Hospital, St Petersburg, Florida.
Robert Peter GaleHaematology Research Centre, Department of Immunology and Inflammation, Imperial College London, London, UK.
Melhem SolhBlood and Marrow Transplant Group of Georgia, Northside Hospital, Atlanta, Georgia.
Mohamed A Kharfan-DabajaDivision of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, Florida.
Miguel Angel DiazDepartment of Hematology/Oncology, Hospital Infantil Universitario Nino Jesus, Madrid, Spain.
Siddhartha GangulyDivision of Hematological Malignancy and Cellular Therapeutics, University of Kansas Health System, Kansas City, Kansas.
Steven GoreSection of Medical Oncology, Department of Internal Medicine, Yale New Haven Hospital, New Haven, Connecticut.
Leo F VerdonckDepartment of Hematology/Oncology, Isala Clinic, Zwolle, The Netherland.
Nasheed M HossainStem Cell Transplant Program, Division of Hematology/Oncology, Department of Medicine, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois.
Natasha KekreBlood & Marrow Transplant Program, Department of Medicine, Ottawa Hospital Ottawa, Ontario, Canada.
Bipin SavaniDivision of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Michael ByrneDivision of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Christopher KanakryExperimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Mitchell S CairoDivision of Pediatric Hematology, Oncology and Stem Cell Transplantation, Department of Pediatrics, New York Medical College, Valhalla, New York.
Stefan CiureaStem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Harry C SchoutenDepartment of Hematology, Academische Ziekenhuis, Maastricht, The Netherlands.
Christopher BredesonBlood & Marrow Transplant Program, Department of Medicine, Ottawa Hospital Ottawa, Ontario, Canada.
Reinhold MunkerDivision of Medical Oncology, Markey Cancer Center, University of Kentucky School of Medicine, Lexington, Kentucky.
Hillard LazarusDepartment of Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio.
Jean-Yves CahnDepartment of Hematology, CHU Grenoble Alpes, Grenoble, France.
Marjolein van Der PoelDepartment of Internal Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands.
David RizzieriDivision of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, North Carolina.
Jean A YaredBlood & Marrow Transplantation Program, Division of Hematology/Oncology, Department of Medicine, Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, Maryland.
Cesar FreytesHematopoietic Stem Cell Transplant Program, Texas Transplant Institute, San Antonio, Texas.
Jan CernyDivision of Hematology/Oncology, Department of Medicine, University of Massachusetts Medical Center, Worcester, Massachusetts.
Mahmoud AljurfDepartment of Oncology, King Faisal Specialist Hospital Center & Research, Riyadh, Saudi Arabia.
Neil D PalmisianoSidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
Attaphol PawarodeBlood and Marrow Transplantation Program, Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan.
Vera Ulrike BacherDepartment of Hematology, Inselspital, Bern University Hospital, University of Bern, Switzerland.
Michael R GrunwaldDepartment of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina.
Sunita NathanSection of Bone Marrow Transplantation and Cellular Therapy, Division of Hematology, Oncology and Cell Therapy, Department of Internal Medicine, Rush Medical College, Chicago, Illinois.
Baldeep WirkBone Marrow Transplant Program, Penn State Cancer Institute, Hershey, Pennsylvania.
Gerhard C HildebrandtDivision of Medical Oncology, Markey Cancer Center, University of Kentucky School of Medicine, Lexington, Kentucky.
Sachiko SeoDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan.
Richard F OlssonDepartment of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; Centre for Clinical Research Sormland, Uppsala University, Sweden.
Biju GeorgeDepartment of Haematology, Christian Medical College, Vellore, India.
Marcos de LimaDepartment of Medicine, Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, Ohio.
Christopher S HouriganLaboratory of Myeloid Malignancies, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland.
Brenda M SandmaierDivision of Medical Oncology, University of Washington and Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Mark LitzowDivision of Hematology and Transplant Center, Mayo Clinic Rochester, Rochester, Minnesota.
Partow KebriaeiStem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Wael SaberDivision of Biostatistics, Medical College of Wisconsin, Milwaukee, Wisconsin.
Daniel WeisdorfDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, 96.
Medical College of Wisconsin · USLevine Cancer Institute · USThe University of Texas MD Anderson Cancer Center · USUniversity of Minnesota · USVanderbilt University Medical Center · USBeth Israel Deaconess Medical Center · USCentre Hospitalier Universitaire de Grenoble · FRChristian Medical College & Hospital · INDokkyo Medical University · JPDuke University · USFred Hutch Cancer Center · USHospital de Sant Pau · ESHospital Infantil Universitario Niño Jesús · ESImperial College London · GBJohns Hopkins All Children's Hospital · USKing Faisal Specialist Hospital & Research Centre · SAMaastricht University Medical Centre · NLMayo Clinic · USMayo Clinic in Florida · USMemorial Sloan Kettering Cancer Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MData Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2MYale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MBlood and Marrow Transplant Clinical Trials Network DCC- The Medical College of Wisconsin, Inc.U24HL138660 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI Steven M. DeVine, Mehdi Hussain Hamadani · 2017 to 2026
$71.4MTherapeutic Potential of Adaptive NK Cells in Cancer and TransplantationP01CA111412 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI FELICES, MARTIN · 2005 to 2025
$38.2MDetection, prevention and treatment of acute myeloid leukemia (AML) relapse.ZIAHL006163 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI HOURIGAN, CHRISTOPHER · 2013 to 2023
$21.0MDeciphering the efficacy of posttransplant cyclophosphamide in haplo transplantZIABC011659 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KANAKRY, CHRISTOPHER · 2015 to 2025
$18.5MRandomized study of low versus moderate dose busulfan in transplant for severe combined immunodeficiencyU01AI126612 · NIAID · CHILDREN'S HOSPITAL OF LOS ANGELES · PI KEAN, LESLIE S, PULSIPHER, MICHAEL A · 2017 to 2023
$8.5MThe role of TCOF1 in germline predisposition to and in leukemic transformation of chronic myelomonocytic leukemiaR01CA152108 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Jing Zhang · 2011 to 2026
$5.4MIdentifying Predictors of Poor Health-Related Quality-of-life among Pediatric Hematopoietic Stem Cell DonorsR01HL131731 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PULSIPHER, MICHAEL A, SWITZER, GALEN E. · 2018 to 2022
$3.6MSelection of Allogeneic Hematopoietic Cell Donor Based on KIR and HLA GenotypesR01HL129472 · NHLBI · SLOAN-KETTERING INST CAN RESEARCH · PI HSU, KATHARINE C · 2015 to 2019
$2.6MHematopoietic Stem Cell Transplantation for Young Adults with SCD - DCCU01HL128568 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI EAPEN, MARY, MENDIZABAL, ADAM M. · 2015 to 2019
$1.7MNCATS NIH HHS UL1 TR001863NCI NIH HHS P01 CA111412NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA152108NCI NIH HHS R01 CA231141NCI NIH HHS U24 CA076518NHLBI NIH HHS R01 HL126589NHLBI NIH HHS R01 HL129472NHLBI NIH HHS R01 HL131731NHLBI NIH HHS R21 HL140314NHLBI NIH HHS U01 HL128568NHLBI NIH HHS U24 HL138660NIAID NIH HHS U01 AI126612
Abstract
Compared with reduced-intensity conditioning (RIC), myeloablative conditioning (MAC) is generally associated with lower relapse risk after allogeneic hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS). However, disease-specific risk factors in AML/MDS can further inform when MAC and RIC may yield differential outcomes. We analyzed HCT outcomes stratified by the Disease Risk Index (DRI) in 4387 adults (age 40 to 65 years) to identify the impact of conditioning intensity. In the low/intermediate-risk DRI cohort, RIC was associated with lower nonrelapse mortality (NRM) (hazard ratio [HR], .74; 95% confidence interval [CI], .62 to .88; P < .001) but significantly greater relapse risk (HR, 1.54; 95% CI, 1.35 to 1.76; P < .001) and thus inferior disease-free survival (DFS) (HR, 1.19; 95% CI, 1.07 to 1.33; P = .001). In the high/very high-risk DRI cohort, RIC was associated with marginally lower NRM (HR, .83; 95% CI, .68 to 1.00; P = .051) and significantly higher relapse risk (HR, 1.23; 95% CI, 1.08 to 1.41; P = .002), leading to similar DFS using either RIC or MAC. These data support MAC over RIC as the preferred conditioning intensity for patients with AML/MDS with low/intermediate-risk DRI, but with a similar benefit as RIC in high/very high-risk DRI. Novel MAC regimens with less toxicity could benefit all patients, but more potent antineoplastic approaches are needed for the high/very-high risk DRI group.
Indexed as
Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteMyelodysplastic SyndromesAdultAgedDisease-Free SurvivalHumansMiddle AgedRetrospective StudiesTransplantation ConditioningTransplantation, HomologousAMLDRIMDSMyeloablativeRIC
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.